LAVISTINA

This brand name is authorized in Poland

Active ingredients

The drug LAVISTINA contains one active pharmaceutical ingredient (API):

1 Betahistine
UNII 49K58SMZ7U - BETAHISTINE HYDROCHLORIDE

Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H1 receptors and moderate antagonist activity at H3 receptors. Betahistine may increase blood flow to the cochlear region as well as to the whole brain.

Read about Betahistine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N07CA01 Betahistine N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations
Discover more medicines within N07CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100017836, 100182512, 100193562

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈